Development-stage Biolink promotes dialysis access device as likely to make substantial savings
This article was originally published in Clinica
Executive Summary
Biolink, a five-year old US development-stage company, is attempting to remove the problems associated with vessel exhaustion in haemodialysis. Its device looks likely to reduce patient costs, cut down hospitalisation and even prevent infection-related deaths, by adapting concepts from oncology practice.